The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20121034: Calumet Specialty Products Partners, L.P.; Royal Purple, Inc.
20121031: Paul G. Desmarais; IntegraMed America, Inc.
20121025: WPP plc; General Atlantic Partners 83, LP
20120974: Verizon Communications Inc.; Apollo Investment Fund V, L.P.
20121023: EQT VI (No.1) Limited Partnership; BSN medical Luxembourg Holding S.a.r.l.
20121020: ORG Chemical Holdings, LLC; McFerrin Dynasty Trust
20121019: salesforce.com, inc.; Buddy Media, Inc.
20121018: Wesco International, Inc.; Caxton-Iseman (Conney), L.P.
Sony/EMI
20120995: General Dynamics Corporation; Jerrold L. Miller
Andrew Torregrossa & Sons, Inc., Andrew L. Torregrossa, and John L. Torregrossa, U.S.
20120927: Pearson plc; GlobalEnglish Corporation
Perrigo Company and Paddock Laboratories, Inc., In the Matter of
On 7/26/2011, the Commission required generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to sell six generic drugs under a proposed settlement resolving charges that Perrigo’s proposed $540 million acquisition of Paddock would be anticompetitive. The proposed settlement also contains provisions to ensure future competition in the market for generic testosterone gel product. On 6/26/2012, the FTC issued a modified final order that required the companies to sell six generic drugs to Watson Pharmaceuticals, Inc.